Updates & Impacts - 2022 Program Agenda
2022 Agenda
Target Audience
This activity is intended for oncologists, hematologists, pathologists, clinical scientists, nurse practitioners, physician assistants, nurses, and pharmacists engaged in the care of patients with hematologic malignancies
Educational ObjectivesAfter completing this activity, the participant should be better able to:
- Evaluate recent clinical treatment regimens that are being investigated in patients with indolent and aggressive forms of lymphoma
- Review current and emerging approaches to the treatment of patients with multiple myeloma, including novel combinations, BCMA-targeted therapies, cell signaling inhibitors, and chemotherapy formulations
- Debate recent data of therapies for patients with CLL, as well as how various patient- and disease-related factors impact selection and sequencing of agents
- Compare and contrast the safety and efficacy of novel approaches for the care of patients with acute leukemia, including acute myeloid leukemia and acute lymphoblastic leukemia
- Assess the clinical trial results of treatment strategies that are being investigated in patients with myeloproliferative neoplasms, including MF, PV, MDS, and others
Time(EST)
Presentation
Faculty
9:30 AM – 9:40 AM
Welcome and Meeting Overview
John Leonard, MD and Mark Heaney, MD, PhD
Lymphoma Session
9:40 AM – 9:55 AM
New Data in Upfront and Relapsed Aggressive B-cell Lymphoma
John Leonard, MD
9:55 AM – 10:10 AM
What’s New in Therapy of Indolent and Mantle Cell Lymphoma
Peter Martin, MD
10:10 AM – 10:25 AM
Updates in the Management of Hodgkin and T-cell Lymphomas
Barbara Pro, MD
10:25 AM – 10:40AM
Key Conversations: Lymphoma panel discussion and Q&A moderated by Dr. John Leonard
Community Physicians
BREAK
Multiple Myeloma and CAR T-Cell Therapy Session
10:55 AM – 11:10 AM
New Data in Upfront Management of Multiple Myeloma
Ruben Niesvizky MD
11:10 AM – 11:25 AM
How to Integrate Novel Approaches in the Treatment of Relapsed/Refractory Myeloma
Suzanne Lentzsch, MD, PhD
11:25 AM – 11:40 AM
What are the latest approaches for using CAR T-cell therapy for hematologic malignancies?
Koen Van Besien, MD
11:40 AM – 11:55 AM
Key Conversations: Multiple myeloma panel discussion and Q&A moderated by Dr. John Leonard
Community Physicians
LUNCH BREAK
CLL Session
12:25 PM – 12:40 PM
New therapeutic options in frontline CLL
Richard Furman, MD, FACS
12:40 PM – 12:55 PM
Updates in management for relapsed and refractory CLL
Nicole Lamanna, MD
1:10 PM – 1:25 PM
Key Conversations: CLL panel discussion and Q&A moderated by Dr. Mark Heaney
Community Physicians
BREAK
Acute Leukemia Session
1:40 PM – 1:55 PM
What’s new in upfront treatment of AML?
Joseph Jurcic, MD
1:55 PM – 2:10 PM
New direction in the treatment of Relapsed and Refractory AML
Gail Roboz, MD
2:10 PM – 2:25 PM
Hot Topics in the Management of AML
Andrew Lipsky, MD
2:25PM – 2:40 PM
Key Conversations: “Acute Leukemia Panel Discussion” and Q&A moderated by Dr. Mark Heaney
Community Physicians
BREAK
MDS/MPN Session
3:05 PM – 3:15 PM
New Treatments for MPNs: Novel Agents and Early Phase Trials
Ellen Ritchie, MD
3:15 PM – 3:30 PM
Later Phase Trials for MPNs, CML and Systemic Mastocytosis
Mark Heaney, MD, PhD
3:30 PM – 3:45 PM
New developments in nonmalignant hematology
Layla van Doren, MD
3:45 PM – 4:00 PM
Key Conversations: MDS/MPN panel discussion and Q&A moderated by Dr. Mark Heaney
Community Physicians
4:00 PM – 4:05 PM
Closing summary and post session survey
Mark Heaney, MD, PhD
